On December 4-5, 2021, hosted by the Cancer Drug Research Committee of the Chinese Association of Chinese Medicine, Peking University International Hospital, Guang'anmen Hospital of the Chinese Academy of Chinese Medical Sciences, Tongde Hospital of Zhejiang Province, and the Research and Development Working Committee of Chinese and Western Medicines of the Chinese Association of Chinese Medicine The "Second China Fusion of Chinese and Western Oncology Conference and the 2021 Academic Annual Meeting of the Cancer Drug Research Professional Committee of the Chinese Association of Traditional Chinese Medicine" co-organized in Beijing was grandly held.

Coinciding with the opening year of the "14th Five-Year Plan" Healthy China Strategy, the theme of the meeting is "Chinese and Western Joint Prevention and Control and Healthy China". Academicians Sun Yan, Zhang Boli, and Yu Jinming of the Chinese Academy of Western medicine clinical experts and methodological experts will come to the site or gather in the cloud to witness this high-standard and high-quality "integration of Chinese and Western" academic ceremony.

At the opening ceremony of the conference, Sun Yan, a consultant of the special committee and academician of the Chinese Academy of Engineering, delivered a speech and interpreted the theme of the conference - "integration of Chinese and Western medicine, symbiosis of medicine, combination of prevention and treatment". Then, Academician Zhang Boli of the Chinese Academy of Engineering delivered a speech to the conference and interpreted the theme of this meeting——“To find a way to prevent and treat tumors with Chinese characteristics and the integration of Chinese and Western development”.

The conference set up the main venue and sub-forums. In the morning, the main venue held the release ceremony of "Guidelines for the Clinical Application of Chinese Proprietary Medicines in the Treatment of Cancer-Induced Fatigue", the Summit Forum on the Integration and Integration of Chinese and Western Medicine, and the "Combination of Traditional Chinese and Western Medicine to Prevent and Treat Adverse Reactions Related to Malignant Tumor Treatment". Clinical application guidelines" work meeting.

Mengyang Pharmaceutical brought the 2021 medical insurance exclusive product Shengbai oral liquid (mixture) (medical insurance code 944) to report at the "Guidelines for Clinical Application of Adverse Reactions Related to Treatment of Malignant Tumors Combined with Traditional Chinese and Western Medicine" work meeting. Quantitative indicators can be used to evaluate the curative effect of the prevention and treatment of inhibition, and evidence-based medical evidence is sufficient, which has been highly appreciated and recognized by the members of the expert group.

In the afternoon, three forums, "Summit Forum on Integrative Chinese and Western Medicine Radiation Therapy for Tumors", "Tumor Immune Regulation and Precise Prevention and Treatment", and "Technical Innovation and Application of Chinese and Western Medicine in Diagnosis and Treatment of Tumors" were held together.

Professor Liu Shuo from Guang'anmen Hospital of China Academy of Chinese Medical Sciences conducted the "Report on Clinical Research Progress of Shengbai Oral Liquid (Mixture)" at the forum of "Tumor Immunity Regulation and Precise Prevention and Control". Part of the effectiveness and safety of the product has been reported in detail.

At the meeting, Professor Liu Shuo also made an outlook on the prevention and treatment of myelosuppression with the combination of traditional Chinese and Western medicine. He believes that: Traditional Chinese medicine is based on the theory of "treating the disease before the disease" and advocating the principle of putting prevention first and combining prevention and treatment. The overall concept and syndrome differentiation can not only prevent and treat myelosuppression, but also treat the tumor itself and other complications. Shengbai oral liquid (mixture) produced by Mengyang Pharmaceutical Co., Ltd. still insists on carrying out multi-center clinical research with large samples, in line with evidence-based medical norms and the scientific evaluation system of traditional Chinese medicine, and digging out the theory and mechanism of Chinese medicine prescriptions. Combining the theme of the conference with "integration of Chinese and Western medicine, symbiosis of medicine, and combination of prevention and treatment", it also added a rich touch to the academic ceremony of "integration of Chinese and Western medicine".

Through the convening of this event, it is believed that the integration of traditional Chinese and Western medicine, as a medical theory system with Chinese characteristics, will definitely play a role in cancer prevention and treatment, "walk out a path of cancer prevention and treatment with Chinese characteristics and the integration of Chinese and Western medicine", and ultimately improve the quality of cancer. clinical outcomes for patients.